Prosecution Insights
Last updated: April 19, 2026

Examiner: KENYON, JOHN S

Tech Center 1600 • Art Units: 1622 1625

This examiner grants 80% of resolved cases

Performance Statistics

80.0%
Allow Rate
+20.0% vs TC avg
961
Total Applications
+17.8%
Interview Lift
936
Avg Prosecution Days
Based on 921 resolved cases, 2023–2026

Rejection Statute Breakdown

2.9%
§101 Eligibility
23.6%
§102 Novelty
15.2%
§103 Obviousness
38.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17249457 CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS Final Rejection Genentech, Inc.
18558351 CRYSTAL FORM IV OF ORGANIC ACID SALTS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND PREPARATION METHOD THEREOF Non-Final OA LG CHEM, LTD.
17934277 Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes Non-Final OA Regeneron Pharmaceuticals, Inc.
19097371 PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS Final Rejection Biohaven Therapeutics Ltd.
18113369 DIAGNOSIS METHODS, DIAGNOSTIC AGENTS, AND THERAPEUTIC AGENTS AGAINST ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION, AND SCREENING METHODS FOR THESE AGENTS Non-Final OA National University Corporation Tokyo Medical and Dental University
17784841 OPHTHALMIC COMPOSITIONS COMPRISING D2O Non-Final OA Sydnexis, Inc.
18194867 FORMULATIONS AND METHODS FOR IMPROVING AVIAN HEALTH Non-Final OA CORNELL UNIVERSITY
18530467 COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS Non-Final OA Cedars-Sinai Medical Center
17777910 TRPM8 MODULATORS Non-Final OA Givaudan SA
18031632 TETRACYCLINE DERIVATIVES FOR TREATING NEURODEGENERATIVE OR NEUROINFLAMMATORY DISEASES Non-Final OA UNIVERSITE PARIS-SACLAY
17998219 CIRCULAR RNA COMPOSITIONS AND METHODS Non-Final OA Orna Therapeutics, Inc.
17795670 FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND PRODUCTION METHOD THEREFOR Final Rejection UNIMATEC CO., LTD.
18269916 A Tracer Compound and a Preparation Method Thereof Non-Final OA Turun Yliopisto
18497586 EGFR Degraders and Associated Methods of Use Non-Final OA BeiGene Switzerland GmbH
18022869 EXTRACTION METHOD AND MIXTURE OF SUBSTANCES Non-Final OA K.D. PHARMA BEXBACH GMBH
18196567 ADMINISTRATION OF A PSYCHEDELIC COMPOUND Non-Final OA Reset Pharmaceuticals, Inc.
18031229 PROCESS TO PREPARE A CYCLIC CARBONATE Non-Final OA NEW GREEN WORLD B.V.
18132120 CRYSTAL FORM OF COMPOUND AND FUMARIC ACID, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING CORONAVIRUS-INDUCED DISEASES Final Rejection NANJING GRITPHARMACO.,LTD.
18247943 A LIQUID INJECTABLE COMPOSITION OF DONEPEZIL Non-Final OA PTS Consulting, LLC
18025797 ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS Non-Final OA THE UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
18016299 AQUEOUS PHARMACEUTICAL COMPOSITION COMPRISING A P2Y12 RECEPTOR ANTAGONIST Non-Final OA Viatris Asia Pacific Ptd. Ltd.
17998562 METHODS OF USING BILE ACIDS TO TREAT VIRAL INFECTIONS Non-Final OA HOFFMAN TECHNOLOGIES LLC
17929609 COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING AMYOTROPHIC LATERAL SCLEROSIS IN PATIENTS WITH HYPOFUNCTIONAL ANTI-TRYPSIN ACTIVITY Non-Final OA Motor Life Sciences, LLC
17909171 SUBSTITUTED PYRIDAZINE COMPOUND Non-Final OA NICO Therapeutics, Inc.
17904144 5-HT3 RECEPTOR MODULATOR, THE CRYSTALLINE FORM, METHODS OF MAKING, AND USE THEREOF Final Rejection Dejian XIE
17794390 PD-1/PD-L1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Final Rejection ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
17776428 PHARMACEUTICAL COMPOSITION OF (S)-KETOROLAC AND PREPARATION METHOD THEREFOR Final Rejection NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD.
17769924 DIRECTED CONJUGATION TECHNOLOGIES Final Rejection KLEO PHARMACEUTICALS, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month